{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:53:02Z","timestamp":1793713982860,"version":"4.6.1"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:00:00Z","timestamp":1695513600000},"content-version":"am","delay-in-days":297,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA035714"],"award-info":[{"award-number":["R01DA035714"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA047924"],"award-info":[{"award-number":["R01DA047924"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.neuropharm.2022.109239","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T01:46:37Z","timestamp":1663379197000},"page":"109239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["SRI-32743, a novel allosteric modulator, attenuates HIV-1 Tat protein-induced inhibition of the dopamine transporter and alleviates the potentiation of cocaine reward in HIV-1 Tat transgenic mice"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9075-4866","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela M.","family":"Quizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Adeniran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Jim\u00e9nez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Cirino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shainnel O.","family":"Eans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haylee R.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure S.","family":"Deliscar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"O'Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra K.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Ofori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh H.","family":"Vekariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Moukha-Chafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramaniam","family":"Ananthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne E.","family":"Augelli-Szafran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Guo","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay P.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109239_bib1","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1523\/JNEUROSCI.15-05-03429.1995","article-title":"Dopamine D2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys","volume":"15","author":"Arnsten","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109239_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0149-7634(94)00021-R","article-title":"Conditioned place preference using opiate and stimulant drugs: a meta-analysis","volume":"19","author":"Bardo","year":"1995","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109239_bib3","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1021\/j100142a004","article-title":"A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model","volume":"97","author":"Bayly","year":"1993","journal-title":"J. Phys. Chem."},{"key":"10.1016\/j.neuropharm.2022.109239_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/026988110001400304","article-title":"HIV dementia: the role of the basal ganglia and dopaminergic systems","volume":"14","author":"Berger","year":"2000","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002030-199401000-00010","article-title":"Cerebrospinal fluid dopamine in HIV-1 infection","volume":"8","author":"Berger","year":"1994","journal-title":"AIDS"},{"key":"10.1016\/j.neuropharm.2022.109239_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002030-199901140-00003","article-title":"Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis","volume":"13","author":"Brack-Werner","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.neuropharm.2022.109239_bib7","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1523\/JNEUROSCI.6146-08.2009","article-title":"Endogenous kappa opioid activation mediates stress-induced deficits in learning and memory","volume":"29","author":"Carey","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109239_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbr.2011.12.019","article-title":"Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse","volume":"229","author":"Carey","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109239_bib9","series-title":"Amber 16","author":"Case","year":"2016"},{"key":"10.1016\/j.neuropharm.2022.109239_bib10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.neuroimage.2008.05.011","article-title":"Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse","volume":"42","author":"Chang","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuropharm.2022.109239_bib11","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/cercor\/11.12.1136","article-title":"Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands","volume":"11","author":"Cools","year":"2001","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2022.109239_bib12","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.biopsych.2011.03.028","article-title":"Inverted-U-shaped dopamine actions on human working memory and cognitive control","volume":"69","author":"Cools","year":"2011","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109239_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/13550280009015824","article-title":"Detection of HIV-1 Tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy","volume":"6","author":"Del Valle","year":"2000","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00002826-200007000-00004","article-title":"Decreased homovanilic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1-infected patients","volume":"23","author":"di Rocco","year":"2000","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/bph.12132","article-title":"The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting kappa opioid receptor antagonism in the CNS after oral administration","volume":"169","author":"Eans","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109239_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.biopsych.2012.09.026","article-title":"Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice","volume":"73","author":"Fitting","year":"2013","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109239_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbr.2016.04.009","article-title":"Object recognition impairment and rescue by a dopamine D2 antagonist in hyperdopaminergic mice","volume":"308","author":"Franca","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109239_bib19","series-title":"Gaussian 09","author":"Frisch","year":"2009"},{"key":"10.1016\/j.neuropharm.2022.109239_bib20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11481-013-9443-y","article-title":"Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND","volume":"8","author":"Gaskill","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib21","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.2353\/ajpath.2009.081067","article-title":"Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse","volume":"175","author":"Gaskill","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108232","article-title":"Dopamine receptor activation increases HIV entry into primary human macrophages","volume":"9","author":"Gaskill","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2022.109239_bib23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nrn.2016.57","article-title":"Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression","volume":"17","author":"Grace","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109239_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbr.2014.10.025","article-title":"Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents","volume":"285","author":"Grayson","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109239_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1196\/annals.1316.006","article-title":"Molecular mechanisms underlying the rewarding effects of cocaine","volume":"1025","author":"Hall","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2022.109239_bib26","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1212\/WNL.0b013e318200d727","article-title":"HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study","volume":"75","author":"Heaton","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2022.109239_bib27","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00702-013-1086-x","article-title":"Increases in CSF dopamine in HIV patients are due to the dopamine transporter 10\/10-repeat allele which is more frequent in HIV-infected individuals","volume":"120","author":"Horn","year":"2013","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2022.109239_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/13550280009013158","article-title":"Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues","volume":"6","author":"Hudson","year":"2000","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s11481-019-09867-w","article-title":"Inhibitory control deficits associated with upregulation of CB1R in the HIV-1 tat transgenic mouse model of hand","volume":"14","author":"Jacobs","year":"2019","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/1531-8249(20010201)49:2<230::AID-ANA43>3.0.CO;2-O","article-title":"HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors","volume":"49","author":"Johnston","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bbr.2016.05.034","article-title":"Effects of HIV\/TAT protein expression and chronic selegiline treatment on spatial memory, reversal learning and neurotransmitter levels in mice","volume":"311","author":"Kesby","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109239_bib32","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0002-9440(10)64304-0","article-title":"Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline","volume":"162","author":"Kim","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib33","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.micinf.2005.11.014","article-title":"HIV tat and neurotoxicity","volume":"8","author":"King","year":"2006","journal-title":"Microb. Infect."},{"key":"10.1016\/j.neuropharm.2022.109239_bib34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s007020200032","article-title":"Involvement of dopamine in the progression of AIDS dementia complex","volume":"109","author":"Koutsilieri","year":"2002","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2022.109239_bib35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00002512-200016050-00006","article-title":"Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease","volume":"16","author":"Kulisevsky","year":"2000","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neuropharm.2022.109239_bib36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/13550280902973952","article-title":"Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains","volume":"15","author":"Kumar","year":"2009","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13365-010-0003-4","article-title":"Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance","volume":"17","author":"Kumar","year":"2011","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112642","article-title":"Deficit in working memory and abnormal behavioral tactics in dopamine transporter knockout rats during training in the 8-arm maze","volume":"390","author":"Kurzina","year":"2020","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109239_bib39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3109\/13550281003735709","article-title":"Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain","volume":"16","author":"Lamers","year":"2010","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib40","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/jnr.490280313","article-title":"Cerebrospinal fluid catecholamine metabolites in HIV-infected patients","volume":"28","author":"Larsson","year":"1991","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2022.109239_bib41","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1523\/JNEUROSCI.1931-17.2018","article-title":"Pronounced hyperactivity, cognitive dysfunctions, and BDNF dysregulation in dopamine transporter knock-out rats","volume":"38","author":"Leo","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109239_bib42","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ana.10844","article-title":"HIV-1 Tat inhibits long-term potentiation and attenuates spatial learning [corrected]","volume":"55","author":"Li","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib43","doi-asserted-by":"crossref","first-page":"12190","DOI":"10.1523\/JNEUROSCI.3019-08.2008","article-title":"NMDA receptor activation by HIV-Tat protein is clade dependent","volume":"28","author":"Li","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109239_bib44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12640-009-9047-8","article-title":"Role of Tat protein in HIV neuropathogenesis","volume":"16","author":"Li","year":"2009","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2022.109239_bib45","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00213-011-2536-5","article-title":"Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models","volume":"220","author":"Lyon","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109239_bib46","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0547-20.2021","article-title":"HIV-1 tat and morphine differentially disrupt pyramidal cell structure and function and spatial learning in hippocampal area CA1: continuous versus interrupted morphine exposure","volume":"8","author":"Marks","year":"2021","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2022.109239_bib47","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13365-016-0447-2","article-title":"HIV-1 Tat causes cognitive deficits and selective loss of parvalbumin, somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron subpopulations","volume":"22","author":"Marks","year":"2016","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib48","first-page":"599","article-title":"Conditional human immunodeficiency virus transactivator of transcription protein expression induces depression-like effects and oxidative stress","volume":"2","author":"McLaughlin","year":"2017","journal-title":"Biol. Psychiatr. Cogn. Neurosci. Neuroimag."},{"key":"10.1016\/j.neuropharm.2022.109239_bib49","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s11481-013-9464-6","article-title":"Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine transport and transporter conformational transitions","volume":"8","author":"Midde","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib50","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s11481-015-9583-3","article-title":"Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 Tat-induced inhibition of dopamine transport","volume":"10","author":"Midde","year":"2015","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib51","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/syn.20048","article-title":"Identification and characterization of a novel allosteric modulator (SoRI-6238) of the serotonin transporter","volume":"53","author":"Nandi","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2022.109239_bib52","article-title":"Chronic HIV-1 Tat exposure alters anterior cingulate cortico-basal ganglia-thalamocortical synaptic circuitry, associated behavioral control, and immune regulation in male mice","volume":"5","author":"Nass","year":"2020","journal-title":"Brain Behav. Immun. Health"},{"key":"10.1016\/j.neuropharm.2022.109239_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1212\/WNL.37.1.37","article-title":"Movement disorders and AIDS","volume":"37","author":"Nath","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2022.109239_bib54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/135502801300069737","article-title":"Acceleration of HIV dementia with methamphetamine and cocaine","volume":"7","author":"Nath","year":"2001","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib55","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00415-009-5052-3","article-title":"Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV","volume":"256","author":"Obermann","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1196\/annals.1417.003","article-title":"Dopamine signaling in the dorsal striatum is essential for motivated behaviors: lessons from dopamine-deficient mice","volume":"1129","author":"Palmiter","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2022.109239_bib57","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/cercor\/bhz142","article-title":"Balance between transmitter availability and dopamine D2 receptors in prefrontal cortex influences memory functioning","volume":"30","author":"Papenberg","year":"2020","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2022.109239_bib58","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/npp.2013.201","article-title":"Effects of conditional central expression of HIV-1 tat protein to potentiate cocaine-mediated psychostimulation and reward among male mice","volume":"39","author":"Paris","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109239_bib59","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s00213-013-3385-1","article-title":"Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein","volume":"231","author":"Paris","year":"2014","journal-title":"Tat. Psychopharmacol. (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109239_bib60","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1124\/jpet.108.139675","article-title":"Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release","volume":"326","author":"Pariser","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109239_bib61","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11357-020-00268-z","article-title":"HIV-1 Tat promotes age-related cognitive, anxiety-like, and antinociceptive impairments in female mice that are moderated by aging and endocrine status","volume":"43","author":"Qrareya","year":"2021","journal-title":"Geroscience"},{"key":"10.1016\/j.neuropharm.2022.109239_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/srep39048","article-title":"Molecular mechanism: the human dopamine transporter histidine 547 regulates basal and HIV-1 Tat protein-inhibited dopamine transport","volume":"6","author":"Quizon","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109239_bib63","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s11481-021-09984-5","article-title":"Mutations of human DopamineTransporter at Tyrosine88, aspartic Acid 206, and Histidine 547 influence basal and HIV-1 tat-inhibited dopamine transport","volume":"16","author":"Quizon","year":"2021","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib64","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jlb.65.4.458","article-title":"Molecular pathway involved in HIV-1-induced CNS pathology: role of viral regulatory protein","volume":"65","author":"Rappaport","year":"1999","journal-title":"Tat. J. Leukoc Biol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib65","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1124\/jpet.114.222299","article-title":"Studies of the biogenic amine transporters 15. Identification of novel allosteric dopamine transporter ligands with nanomolar potency","volume":"353","author":"Rothman","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109239_bib66","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1124\/jpet.108.149088","article-title":"Studies of the biogenic amine transporters. 13. Identification of \"agonist\" and \"antagonist\" allosteric modulators of amphetamine-induced dopamine release","volume":"329","author":"Rothman","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109239_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218212","article-title":"HIV-1 tat dysregulates the hypothalamic-pituitary-adrenal stress Axis and potentiates oxycodone-mediated psychomotor and anxiety-like behavior of male mice","volume":"21","author":"Salahuddin","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109239_bib68","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/00001756-199603220-00015","article-title":"Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS","volume":"7","author":"Sardar","year":"1996","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2022.109239_bib69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008877-200006000-00008","article-title":"Pharmacological and molecular targets in the search for novel antipsychotics","volume":"11","author":"Scatton","year":"2000","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib70","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00702-010-0415-6","article-title":"Increased dopaminergic neurotransmission in therapy-naive asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses","volume":"117","author":"Scheller","year":"2010","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2022.109239_bib71","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00702-010-0415-6","article-title":"Increased dopaminergic neurotransmission in therapy-naive asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses","volume":"117","author":"Scheller","year":"2010","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2022.109239_bib72","series-title":"The PyMOL Molecular Graphics System","author":"Schrodinger","year":"2015"},{"key":"10.1016\/j.neuropharm.2022.109239_bib73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1124\/jpet.120.266023","article-title":"[(3)H]Dopamine uptake through the dopamine and norepinephrine transporters is decreased in the prefrontal cortex of transgenic mice expressing HIV-1 transactivator of transcription protein","volume":"374","author":"Strauss","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109239_bib74","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1038\/s41598-017-03771-0","article-title":"Allosteric modulatory effects of SRI-20041 and SRI-30827 on cocaine and HIV-1 Tat protein binding to human dopamine transporter","volume":"7","author":"Sun","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109239_bib75","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF02244063","article-title":"Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens","volume":"101","author":"Swerdlow","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109239_bib76","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.neuropharm.2022.109239_bib77","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0301-0082(98)00060-4","article-title":"Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues","volume":"56","author":"Tzschentke","year":"1998","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib78","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1093\/brain\/awh269","article-title":"Decreased brain dopaminergic transporters in HIV-associated dementia patients","volume":"127","author":"Wang","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2022.109239_bib79","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/375497a0","article-title":"Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120","volume":"375","author":"Westendorp","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109239_bib80","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/376572a0","article-title":"Modulation of memory fields by dopamine D1 receptors in prefrontal cortex","volume":"376","author":"Williams","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109239_bib81","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF03033808","article-title":"Dopamine and reward: the anhedonia hypothesis 30 years on","volume":"14","author":"Wise","year":"2008","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2022.109239_bib82","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev-psych-010418-103337","article-title":"Dopamine and addiction","volume":"71","author":"Wise","year":"2020","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.neuropharm.2022.109239_bib83","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1038\/tp.2015.21","article-title":"Pregnenolone sulfate normalizes schizophrenia-like behaviors in dopamine transporter knockout mice through the AKT\/GSK3beta pathway","volume":"5","author":"Wong","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109239_bib84","doi-asserted-by":"crossref","first-page":"11466","DOI":"10.1073\/pnas.97.21.11466","article-title":"Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1","volume":"97","author":"Xiao","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2022.109239_bib85","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/ejn.13406","article-title":"Dopamine receptor activity participates in hippocampal synaptic plasticity associated with novel object recognition","volume":"45","author":"Yang","year":"2017","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109239_bib86","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/acschemneuro.5b00001","article-title":"Molecular mechanism of HIV-1 Tat interacting with human dopamine transporter","volume":"6","author":"Yuan","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109239_bib87","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.4155\/fmc-2016-0138","article-title":"Computational modeling of human dopamine transporter structures, mechanism and its interaction with HIV-1 transactivator of transcription","volume":"8","author":"Yuan","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.109239_bib88","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/syn.20949","article-title":"Recombinant human immunodeficiency virus-1 transactivator of transcription 1-86 allosterically modulates dopamine transporter activity","volume":"65","author":"Zhu","year":"2011","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2022.109239_bib89","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pharmthera.2017.10.007","article-title":"The role of human dopamine transporter in NeuroAIDS","volume":"183","author":"Zhu","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109239_bib90","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1124\/jpet.108.150144","article-title":"HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes","volume":"329","author":"Zhu","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109239_bib91","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2353\/ajpath.2007.070333","article-title":"Protection against human immunodeficiency virus type 1 Tat neurotoxicity by Ginkgo biloba extract EGb 761 involving glial fibrillary acidic protein","volume":"171","author":"Zou","year":"2007","journal-title":"Am. J. Pathol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:20:20Z","timestamp":1758439220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822002982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":91,"alternative-id":["S0028390822002982"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109239","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SRI-32743, a novel allosteric modulator, attenuates HIV-1 Tat protein-induced inhibition of the dopamine transporter and alleviates the potentiation of cocaine reward in HIV-1 Tat transgenic mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109239"}}